Dianthus Therapeutics

Yahoo Finance • 9 days ago

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and WALTHAM, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe aut... Full story

Yahoo Finance • 20 days ago

Dianthus rises as FDA agrees with proposed changes to lead program

[FDA Headquarters] Shares of Dianthus Therapeutics (DNTH [https://seekingalpha.com/symbol/DNTH]) spiked on Thursday after the company announced that the FDA agreed with several proposed changes related to clinical development of its lead... Full story

Yahoo Finance • 28 days ago

Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit

Key Points 5AM Venture Management sold 365,053 shares of Dianthus Therapeutics in the fourth quarter. The quarter-end position value decreased by $14.36 million as a result of the sale, which marked a full exit from Dianthus. The position... Full story

Yahoo Finance • last month

Dianthus Prices $625 Mln Offering To Advance Claseprubart And Broader Autoimmune Pipeline; Stock Up

(RTTNews) - Dianthus Therapeutics, Inc. (DNTH) has priced an upsized $625 million underwritten public offering as the clinical-stage biotech prepares to advance multiple programs targeting severe autoimmune and neuromuscular diseases. The... Full story

Yahoo Finance • last month

Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering

NEW YORK and WALTHAM, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transfo... Full story

Yahoo Finance • last month

Guggenheim Reiterates Buy Rating for Dianthus Therapeutics (DNTH)

Dianthus Therapeutics Inc. (NASDAQ:DNTH) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On March 4, Guggenheim increased the price target on Dianthus Therapeutics Inc. (NASDAQ:DNTH) to $200 from $100. The fi... Full story

Yahoo Finance • last month

Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NEW YORK and WALTHAM, Mass., March 08, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe aut... Full story

Yahoo Finance • 5 months ago

Dianthus Therapeutics GAAP EPS of -$0.97

* Dianthus Therapeutics press release [https://seekingalpha.com/pr/20295274-dianthus-therapeutics-highlights-recent-business-achievements-and-reports-q3-financial] (DNTH [https://seekingalpha.com/symbol/DNTH]): Q3 GAAP EPS of -$0.97. *... Full story

Yahoo Finance • 5 months ago

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results

Claseprubart achieved statistically significant and clinically meaningful improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL), Quantitative Myasthenia Gravis (QMG), and other efficacy measures at Week 13 in Phase 2 MaGic... Full story

Yahoo Finance • 6 months ago

Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting

Positive data from Phase 2 MaGic trial presented for claseprubart in generalized Myasthenia Gravis, including new open-label extension data further supporting potential for 300mg/2mL Q4W dosing Phase 3 gMG trial planned to include QMG ≥10... Full story

Yahoo Finance • 6 months ago

Dianthus to license autoimmune disease candidate in a deal worth up $1B

[Gratitude Concept With Heart Symbol] Eoneren Dianthus Therapeutics (NASDAQ:DNTH [https://seekingalpha.com/symbol/DNTH]) announced a licensing deal worth up to $1B with Nanjing Leads Biolabs on Thursday to obtain exclusive rights to an au... Full story

Yahoo Finance • 6 months ago

Dianthus Therapeutics Enters Into Exclusive DNTH212 Licensing Deal With Nanjing Leads Biolabs

(RTTNews) - Dianthus Therapeutics, Inc. (DNTH), Thursday announced an exclusive licensing agreement with Nanjing Leads Biolabs Co., Ltd. for DNTH212, an investigational, extended half-life bifunctional fusion protein with a potential to ad... Full story

Yahoo Finance • 6 months ago

Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases

DNTH212 is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function Demonstrated superior inhibition of... Full story

Yahoo Finance • 7 months ago

Plus Therapeutics (PSTV) Soars 40% as Firm Seals Partnership with United Healthcare

We recently published Massive Gains: 10 Stocks Investors Can’t Stop Buying. Plus Therapeutics Inc. (NASDAQ:PSTV) is one of the top performers on Thursday. Shares of Plus Therapeutics soared by 39.29 percent on Thursday to finish at $0.563... Full story

Yahoo Finance • 7 months ago

Implied XBI Analyst Target Price: $142

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 7 months ago

Notable Friday Option Activity: GLW, DNTH, CROX

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Corning Inc (Symbol: GLW), where a total volume of 46,563 contracts has been traded thus far today, a contract volume whi... Full story

Yahoo Finance • 7 months ago

Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

NEW YORK and WALTHAM, Mass., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat se... Full story

Yahoo Finance • 7 months ago

Dianthus Therapeutics prices upsized $251M securities offering

Dianthus Therapeutics (NASDAQ:DNTH [https://seekingalpha.com/symbol/DNTH]) has priced [https://seekingalpha.com/pr/20227263-dianthus-therapeutics-inc-announces-pricing-of-upsized-251-million-underwritten-public] its recently announced and... Full story

Yahoo Finance • 7 months ago

Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering

NEW YORK and WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat se... Full story

Yahoo Finance • 7 months ago

Dianthus Therapeutics (DNTH) Hits New High as Drug Trial Sparks Optimism for Blockbuster Potential

We recently published 10 Stocks With Eye-Popping Gains; 7 Soar to Fresh Highs. Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is one of the top performers on Monday. Dianthus Therapeutics soared to a new record high on Monday, as investors che... Full story